We probably should start to use the term “Somatostatin Receptor PET” (SSTR PET) a bit more.  We got used to using the term Ga68 PET but since then we have an approved copper version known as 64Cu Dotatate (commercial brand name in US DETECTNET™).  Now we have another in the clinical trial pipeline and will add others as they come onto my radar.

Ga68 Dotatate/TOC/NOC – click here
Cu64 Dotatate (DetectNET) – click here

A Diagnostic Imaging Study of ⁶⁴Cu-SARTATE™ Using Positron Emission Tomography (PET) on Patients With Known or Suspected NETs

Reference: NCT04438304

Trial status: Recruiting

The purpose of this study is to assess the performance of imaging agent ⁶⁴Cu-SARTATE in participants with known or suspected Gastroenteropancreatic (GEP) NETs as a potential new way to help diagnose this type of cancer.

63 patient multicentre study run in Australia.

Clinical sites:

• Royal North Shore Hospital
• Peter MacCallum Cancer Centre
• Royal Adelaide Hospital

How does it compare to Ga68 Dotatate?

Site: Peter MacCallum Cancer Centre,
Principal Investigator: Prof Rod Hicks

In comparison to ⁶⁸Ga-DOTATATE scans, ⁶⁴Cu-SARTATE^TM imaging in participants with NETs was equivalent at 1 hour, and superior at 4 hours, allowing detection of additional tumours at later time points.

Read more about SARTATE here.

Theranostics.  High late-retention in tumour and clearance from the liver suggests suitability for diagnostic studies as well as for prospective dosimetry for ⁶⁷Cu-SARTATE PRRT (as at Apr 2021, being trialled with Neuroblastoma)

If you can see it, you can detect it.  Read more about Neuroendocrine Neoplasms imaging.